CL2013002419A1 - Polipeptido de membrana soluble en agua; metodo de preparacion; celula que lo comprende; composicion farmaceutica que lo comprendey su uso para tratar un trastorno o enfermedad que esta mediada por la actividad de dicho polipeptido. - Google Patents
Polipeptido de membrana soluble en agua; metodo de preparacion; celula que lo comprende; composicion farmaceutica que lo comprendey su uso para tratar un trastorno o enfermedad que esta mediada por la actividad de dicho polipeptido.Info
- Publication number
- CL2013002419A1 CL2013002419A1 CL2013002419A CL2013002419A CL2013002419A1 CL 2013002419 A1 CL2013002419 A1 CL 2013002419A1 CL 2013002419 A CL2013002419 A CL 2013002419A CL 2013002419 A CL2013002419 A CL 2013002419A CL 2013002419 A1 CL2013002419 A1 CL 2013002419A1
- Authority
- CL
- Chile
- Prior art keywords
- polypeptide
- understands
- mediated
- disorder
- treat
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 239000012528 membrane Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 5
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 5
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161445740P | 2011-02-23 | 2011-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013002419A1 true CL2013002419A1 (es) | 2014-06-06 |
Family
ID=46721234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013002419A CL2013002419A1 (es) | 2011-02-23 | 2013-08-21 | Polipeptido de membrana soluble en agua; metodo de preparacion; celula que lo comprende; composicion farmaceutica que lo comprendey su uso para tratar un trastorno o enfermedad que esta mediada por la actividad de dicho polipeptido. |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US8637452B2 (enExample) |
| EP (1) | EP2709647B1 (enExample) |
| JP (1) | JP6263773B2 (enExample) |
| KR (1) | KR101963914B1 (enExample) |
| CN (2) | CN108752461A (enExample) |
| AU (3) | AU2012220558A1 (enExample) |
| BR (1) | BR112013020969A2 (enExample) |
| CA (1) | CA2827187C (enExample) |
| CL (1) | CL2013002419A1 (enExample) |
| EA (1) | EA201391041A1 (enExample) |
| IL (2) | IL227886A0 (enExample) |
| MX (1) | MX347038B (enExample) |
| SG (2) | SG192646A1 (enExample) |
| WO (1) | WO2012116203A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2827187C (en) | 2011-02-23 | 2019-01-08 | Massachusetts Institute Of Technology | Water soluble membrane proteins and methods for the preparation and use thereof |
| EP2968135A4 (en) | 2013-03-14 | 2016-10-26 | Massachusetts Inst Technology | INJECTABLE, MULTILAYER, SELF-COMPOSITE PEPTIDE RUBBER HYDROGELS FOR LONG-TERM AND DELAYED RELEASE OF HUMAN ANTIBODIES |
| WO2014176524A2 (en) | 2013-04-25 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor |
| WO2014176544A1 (en) * | 2013-04-25 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Water soluble g-protein coupled receptor |
| US10373702B2 (en) * | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
| WO2015149085A2 (en) * | 2014-03-27 | 2015-10-01 | Massachusetts Institute Of Technology | Warer-soluble trans-membrane proteins and methods for the preparation and use thereof |
| US20150370960A1 (en) * | 2014-03-27 | 2015-12-24 | Massachusetts Institute Of Technology | Water-soluble membrane proteins and methods for the preparation and use thereof |
| GB2527286A (en) | 2014-06-11 | 2015-12-23 | Rsr Ltd | Glycoprotein hormone receptor mutations |
| WO2016025781A1 (en) | 2014-08-15 | 2016-02-18 | Cornell University | Compositions and methods for making water-soluble integral membrane proteins |
| CN104198689A (zh) * | 2014-08-25 | 2014-12-10 | 李洁 | 一种检测g-蛋白耦联受体对缩血管物质反应的方法 |
| CN113929766A (zh) * | 2015-02-18 | 2022-01-14 | 麻省理工学院 | 水溶性跨膜蛋白及其制备和使用方法 |
| CN104946674B (zh) * | 2015-06-17 | 2018-05-01 | 山东大学 | 一种腺苷三磷酸/双磷酸酶及其编码基因与应用 |
| CN106749602A (zh) * | 2016-12-30 | 2017-05-31 | 武汉金开瑞生物工程有限公司 | 一种助表达序列及其在无细胞表达adcy2蛋白中的应用 |
| US11293923B2 (en) | 2017-09-01 | 2022-04-05 | Massachusetts Institute Of Technology | S-layer protein 2D lattice coupled detergent-free GPCR bioelectronic interfaces, devices, and methods for the use thereof |
| US11414456B2 (en) | 2017-12-11 | 2022-08-16 | Astellas Pharma Inc. | Cell penetrating peptide |
| CN108245686B (zh) * | 2018-01-15 | 2019-08-13 | 中国科学院昆明动物研究所 | 人grk5基因的用途 |
| US11555060B2 (en) * | 2020-03-25 | 2023-01-17 | Avalon GloboCare Corp. | QTY FC fusion water soluble receptor proteins |
| WO2021202186A2 (en) | 2020-03-31 | 2021-10-07 | Massachusetts Institute Of Technology | Qty fc fusion receptor proteins |
| US11828210B2 (en) | 2020-08-20 | 2023-11-28 | Denso International America, Inc. | Diagnostic systems and methods of vehicles using olfaction |
| US11636870B2 (en) | 2020-08-20 | 2023-04-25 | Denso International America, Inc. | Smoking cessation systems and methods |
| US11760170B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Olfaction sensor preservation systems and methods |
| US11813926B2 (en) | 2020-08-20 | 2023-11-14 | Denso International America, Inc. | Binding agent and olfaction sensor |
| US12251991B2 (en) | 2020-08-20 | 2025-03-18 | Denso International America, Inc. | Humidity control for olfaction sensors |
| US11932080B2 (en) | 2020-08-20 | 2024-03-19 | Denso International America, Inc. | Diagnostic and recirculation control systems and methods |
| US12017506B2 (en) | 2020-08-20 | 2024-06-25 | Denso International America, Inc. | Passenger cabin air control systems and methods |
| US12269315B2 (en) | 2020-08-20 | 2025-04-08 | Denso International America, Inc. | Systems and methods for measuring and managing odor brought into rental vehicles |
| US11881093B2 (en) | 2020-08-20 | 2024-01-23 | Denso International America, Inc. | Systems and methods for identifying smoking in vehicles |
| US11760169B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Particulate control systems and methods for olfaction sensors |
| US12377711B2 (en) | 2020-08-20 | 2025-08-05 | Denso International America, Inc. | Vehicle feature control systems and methods based on smoking |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US544021A (en) * | 1895-08-06 | William k | ||
| NZ260103A (en) * | 1990-11-30 | 1996-10-28 | Bio Technology General Corp | Somatotropin with alterations in the alpha-helix-1 region |
| US5739273A (en) * | 1992-02-12 | 1998-04-14 | Yale University | Transmembrane polypeptide and methods of use |
| JPH09278793A (ja) * | 1996-04-10 | 1997-10-28 | Kinichiro Miura | ポリペプチド |
| US5843678A (en) | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| AU768118B2 (en) * | 1999-03-11 | 2003-12-04 | Gryphon Sciences | Chemical synthesis and use of soluble membrane protein receptor domains |
| EP1254227A2 (en) | 2000-02-11 | 2002-11-06 | Amgen Inc. | Fusion receptor from tnf family |
| US20030143668A1 (en) * | 2001-06-18 | 2003-07-31 | National Institute Of Advanced Industrial | Guanosine triphosphate-binding protein coupled receptors |
| CA2517848A1 (en) | 2003-01-21 | 2004-08-05 | The Trustees Of The University Of Pennsylvania | Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel kcsa |
| DE102004033902A1 (de) * | 2004-07-14 | 2006-02-16 | Zentaris Gmbh | Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's) |
| ATE555126T1 (de) | 2004-08-25 | 2012-05-15 | Janssen Pharmaceutica Nv | Relaxin-chimere polypeptide und deren herstellung und anwendung |
| EP1885746B1 (en) * | 2005-02-08 | 2012-01-11 | Research Development Foundation | Compositions related to soluble g-protein coupled receptors (sgpcrs) |
| BRPI0502759B1 (pt) * | 2005-06-30 | 2014-02-25 | óleo lubrificante e composição lubrificante para uma máquina de refrigeração | |
| WO2007089899A2 (en) * | 2006-02-01 | 2007-08-09 | Oklahoma Medical Research Foundation | Water-soluble (g protein)-coupled receptor protein |
| JO2968B1 (en) | 2006-06-09 | 2016-03-15 | نوفارتيس ايه جي | Polypeptides are a stable insulin-like growth factor |
| CN101688203B (zh) | 2007-03-22 | 2013-12-11 | 赫普泰雅治疗有限公司 | 突变的g蛋白偶联受体及其选择方法 |
| WO2008143910A2 (en) * | 2007-05-18 | 2008-11-27 | University Of Massachusetts | A strategy for cloning and expressing the extracellular domains of receptors as soluble proteins |
| GB0724051D0 (en) | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
| GB0724860D0 (en) | 2007-12-20 | 2008-01-30 | Heptares Therapeutics Ltd | Screening |
| GB0802474D0 (en) | 2008-02-11 | 2008-03-19 | Heptares Therapeutics Ltd | Mutant proteins and methods for selecting them |
| US20110112037A1 (en) | 2008-03-05 | 2011-05-12 | Heptares Therapeutics Limited BioPark | Crystal structure |
| GB0910725D0 (en) | 2009-06-22 | 2009-08-05 | Heptares Therapeutics Ltd | Mutant proteins and methods for producing them |
| US8809525B2 (en) | 2010-02-05 | 2014-08-19 | Heptares Therapeutics Limited | 1,2,4-triazine-4-amine derivatives |
| WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
| US20140031525A1 (en) | 2011-01-21 | 2014-01-30 | Heptares Therapeutics Limited | Mutant g-protein coupled receptor proteins and methods for producing them |
| CA2827187C (en) | 2011-02-23 | 2019-01-08 | Massachusetts Institute Of Technology | Water soluble membrane proteins and methods for the preparation and use thereof |
| WO2012120315A2 (en) | 2011-03-10 | 2012-09-13 | Heptares Therapeutics Limited | Mutant proteins and methods for producing them |
| US20130273585A1 (en) | 2012-04-11 | 2013-10-17 | Gangagen, Inc. | Soluble cytoplasmic expression of heterologous proteins in escherichia coli |
| US20150370960A1 (en) | 2014-03-27 | 2015-12-24 | Massachusetts Institute Of Technology | Water-soluble membrane proteins and methods for the preparation and use thereof |
| US10373702B2 (en) | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
| WO2015149085A2 (en) * | 2014-03-27 | 2015-10-01 | Massachusetts Institute Of Technology | Warer-soluble trans-membrane proteins and methods for the preparation and use thereof |
-
2012
- 2012-02-23 CA CA2827187A patent/CA2827187C/en not_active Expired - Fee Related
- 2012-02-23 CN CN201810684571.XA patent/CN108752461A/zh active Pending
- 2012-02-23 SG SG2013059811A patent/SG192646A1/en unknown
- 2012-02-23 MX MX2013009715A patent/MX347038B/es active IP Right Grant
- 2012-02-23 US US13/403,725 patent/US8637452B2/en active Active
- 2012-02-23 BR BR112013020969A patent/BR112013020969A2/pt not_active Application Discontinuation
- 2012-02-23 JP JP2013555565A patent/JP6263773B2/ja active Active
- 2012-02-23 EA EA201391041A patent/EA201391041A1/ru unknown
- 2012-02-23 AU AU2012220558A patent/AU2012220558A1/en not_active Abandoned
- 2012-02-23 SG SG10201701547VA patent/SG10201701547VA/en unknown
- 2012-02-23 WO PCT/US2012/026353 patent/WO2012116203A1/en not_active Ceased
- 2012-02-23 CN CN2012800096906A patent/CN103458915A/zh active Pending
- 2012-02-23 KR KR1020137024789A patent/KR101963914B1/ko active Active
- 2012-02-23 EP EP12750085.8A patent/EP2709647B1/en active Active
-
2013
- 2013-08-08 IL IL227886A patent/IL227886A0/en active IP Right Grant
- 2013-08-21 CL CL2013002419A patent/CL2013002419A1/es unknown
- 2013-12-13 US US14/105,252 patent/US9309302B2/en active Active
-
2016
- 2016-03-23 US US15/078,036 patent/US10035837B2/en active Active
- 2016-03-29 AU AU2016201914A patent/AU2016201914A1/en not_active Abandoned
-
2017
- 2017-11-15 AU AU2017261525A patent/AU2017261525A1/en not_active Abandoned
-
2018
- 2018-07-13 US US16/034,549 patent/US20180312562A1/en not_active Abandoned
- 2018-08-14 IL IL261151A patent/IL261151A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101963914B1 (ko) | 2019-03-29 |
| KR20140027117A (ko) | 2014-03-06 |
| US20180312562A1 (en) | 2018-11-01 |
| CN103458915A (zh) | 2013-12-18 |
| EP2709647A1 (en) | 2014-03-26 |
| AU2017261525A1 (en) | 2017-12-07 |
| EP2709647A4 (en) | 2015-01-21 |
| US10035837B2 (en) | 2018-07-31 |
| MX2013009715A (es) | 2014-02-28 |
| MX347038B (es) | 2017-04-10 |
| CA2827187A1 (en) | 2012-08-30 |
| US20120252719A1 (en) | 2012-10-04 |
| US9309302B2 (en) | 2016-04-12 |
| JP2014508763A (ja) | 2014-04-10 |
| IL261151A (en) | 2018-10-31 |
| JP6263773B2 (ja) | 2018-01-24 |
| AU2016201914A1 (en) | 2016-04-21 |
| CA2827187C (en) | 2019-01-08 |
| EA201391041A1 (ru) | 2014-04-30 |
| SG10201701547VA (en) | 2017-03-30 |
| BR112013020969A2 (pt) | 2018-07-10 |
| IL227886A0 (en) | 2013-09-30 |
| AU2012220558A1 (en) | 2013-08-22 |
| SG192646A1 (en) | 2013-09-30 |
| CN108752461A (zh) | 2018-11-06 |
| WO2012116203A1 (en) | 2012-08-30 |
| EP2709647B1 (en) | 2019-08-07 |
| US20140243277A1 (en) | 2014-08-28 |
| US20160264640A1 (en) | 2016-09-15 |
| US8637452B2 (en) | 2014-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013002419A1 (es) | Polipeptido de membrana soluble en agua; metodo de preparacion; celula que lo comprende; composicion farmaceutica que lo comprendey su uso para tratar un trastorno o enfermedad que esta mediada por la actividad de dicho polipeptido. | |
| CL2012001539A1 (es) | Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo. | |
| CL2012000620A1 (es) | Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20. | |
| AR089268A1 (es) | Composiciones acuosas para el cuidado bucal | |
| CL2016001405A1 (es) | A peptide mixture | |
| PE20141546A1 (es) | Anticuerpos anti-cd134(ox40) y sus usos de los mismos | |
| ES2572215T3 (es) | Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico | |
| CL2013001935A1 (es) | Formulacion ácida acuosa que comprende un primer péptido enlazado a fluorocarburo; metodo para obtener dicha formulación; uso de dicha formulación para tratar o prevenir infeccion patógena, una enfermedad autoinmunitaria o cancer. | |
| BR112018005746A2 (pt) | composições para higiene bucal e métodos de uso. | |
| DK201001133A (en) | A liquid membrane | |
| CL2013003688A1 (es) | Peptido coagonista del receptor de glucagon/glp-1; conjugado de dicho peptido; composicion farmacéutica; uso del peptido para tratar una enfermedad seleccionada del grupo de síndrome metabólico, diabetes, obesidad, esteatosis hepática y una enfermedad neurodegenerativa. | |
| CL2018000750A1 (es) | Método de redireccionamiento de linfocitos t para el tratamiento de la infección por vih | |
| CL2016002513A1 (es) | Método para preparar amg 416 | |
| BRPI1006443A2 (pt) | proteína ou peptídeo de fusão de meia-vida aumentada in vivo mantidos por liberação sustentada in vivo, e método para aumentar a meia-vida in vivo usando os mesmos. | |
| BR112012010015A2 (pt) | sistema e método de separação osmótica | |
| CL2013003172A1 (es) | Nodo en un sistema de amarre para estructuras flotantes, donde el sistema de amarre tiene al menos una linea de anclaje y al menos dos lineas mas, en que dichas lineas estan aseguradas por medio de una eslinga de linea a un elemento de conexion anular flexible, constituido por una eslinga redonda; y metodo para establecer el sistema de amarre. | |
| AR101742A1 (es) | Agonista del receptor de calcitonina y amilina | |
| AR083273A1 (es) | Metodo y sistema para segmentacion de primer plano de imagenes en tiempo real | |
| BR112012017605A2 (pt) | emulsão acrílica associativa contendo um monómero a base de oxo-álcool, seu método de fabricação, e método para espessamento de uma formulação aquosa usando esta emulsão | |
| UA115436C2 (uk) | Протираковий злитий протеїн | |
| CL2017002233A1 (es) | Un factor de coagulación (fvii o fviia) modificado con tres péptidos carboxi terminal de gonadotropina coriónica unidos al carboxi terminal de fvii o fviia; polinucleótido que lo codifica; composición farmacéutica que lo comprende; uso de fvii o fviia modificado para el tratamiento de coagulación de la sangre o un trastorno de coagulación; método para extender la vía media biológica de un factor de coagulación; método para producir dicho fvii o fviia. | |
| AR086461A1 (es) | Procedimiento de separacion y recuperacion de metal alcalino y aparato de separacion y recuperacion de metal alcalino | |
| CL2014000547A1 (es) | Sistema de bombeo para utilizacion en un deposito de reiduos, comprende: un soporte de bomba, y al menos un elemento de amarre acoplado al soporte de bomba, al menos un elemento de amarre esta configurado para la transicion desde la posicion extendida a la posicion retraida cuando una distancia desde la orilla al soporte de bomba excede un umbral predeterminado como resultado de un cambio en la geometria del deposito de residuos. | |
| CL2013000360A1 (es) | Virus varicela zoster inactivado; composicion farmaceutica que comprende una cantidad de dicho virus; metodos para preparar dicho virus; vacuna que comprende el virus; uso de la vacuna para tratar herpes zóster. | |
| GT201200335A (es) | Procedimiento para la preparacion de diàcido 3,6.9- triaza-3,6,9-tris(carboximetil) -4-(4-etoxibencil)-undecanoico cristitalino y el uso para la preparacion de promovisto |